Targeted Oncology7h
The Targeted Pulse: Check Out Positive and Negative Updates in Head and Neck Cancer, and How the FDA is Handling Advancements in Lung Cancer Treatment
HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with ...